[The role of intestinal microflora in the development of complications of hepatic cirrhosis-associated portal hypertension]
- PMID: 17926483
[The role of intestinal microflora in the development of complications of hepatic cirrhosis-associated portal hypertension]
Abstract
Intestinal microflora plays an important role in the pathogenesis of hepatic cirrhosis (HC) complications. These patients are at a high risk of bacterial infections, mainly spontaneous ascitis infection or spontaneous bacterial peritonitis, pneumonia, or pleural empyema. Other HC complications, such as varicose vein hemorrhage, gastropathy, hepatorenal and hepatopulmonary syndromes, and portopulmonary hypertension, develop mainly due to portal hypertension. Portal hypertension is primarily caused by increased intrahepatic resistance, while after the forming of collateral circulation high portal pressure is maintained by increased splanchnic blood inflow secondary to vasodilatation. Itraorganic vasodilatation initiates hyperdynamic circulatory status, which exacerbates HC complications. Intestinal microflora plays a role in the development of both infectious complications and hyperdynamic circulatory status in HC. The article contains evidence of the influence of intestinal microflora on the development of HC complications.
Similar articles
-
Gut microflora in the pathogenesis of the complications of cirrhosis.Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):353-72. doi: 10.1016/j.bpg.2003.10.005. Best Pract Res Clin Gastroenterol. 2004. PMID: 15123075 Review.
-
[Circulatory dysfunction syndrome associated with liver cirrhosis].Przegl Epidemiol. 2005;59(2):549-58. Przegl Epidemiol. 2005. PMID: 16190566 Review. Polish.
-
Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.Mol Aspects Med. 2008 Feb-Apr;29(1-2):119-29. doi: 10.1016/j.mam.2007.09.006. Epub 2007 Oct 24. Mol Aspects Med. 2008. PMID: 18036654 Review.
-
[Pathogenesis of portal hypertension].Rev Invest Clin. 2005 Jul-Aug;57(4):596-607. Rev Invest Clin. 2005. PMID: 16315644 Review. Spanish.
-
Portal hypertension.Curr Opin Gastroenterol. 2006 May;22(3):254-62. doi: 10.1097/01.mog.0000218962.93806.9a. Curr Opin Gastroenterol. 2006. PMID: 16550040 Review.
Cited by
-
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.World J Gastroenterol. 2018 Sep 7;24(33):3738-3748. doi: 10.3748/wjg.v24.i33.3738. World J Gastroenterol. 2018. PMID: 30197479 Free PMC article. Review.
-
Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis.World J Hepatol. 2023 Apr 27;15(4):525-537. doi: 10.4254/wjh.v15.i4.525. World J Hepatol. 2023. PMID: 37206649 Free PMC article. Review.
-
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.Gastroenterol Hepatol Bed Bench. 2022 Summer;15(3):194-203. doi: 10.22037/ghfbb.v15i3.2549. Gastroenterol Hepatol Bed Bench. 2022. PMID: 36311966 Free PMC article. Review.
-
Current approaches to the management of patients with cirrhotic ascites.World J Gastroenterol. 2019 Jul 28;25(28):3738-3752. doi: 10.3748/wjg.v25.i28.3738. World J Gastroenterol. 2019. PMID: 31391769 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Medical